ARTELO BIOSCIENCES INC (ARTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.04-2.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARTL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to raise capital via private placements, at-the-market equity programs, and promissory notes to support operations and growth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on controlling operating losses and reducing negative cash flow to sustain operations.
Management stated managing operating losses and negative cash flow as a priority in 7 quarters from 2024-Q3 through 2026-Q2. Operating income worsened from -$1.2M in 2024-Q3 to -$2.5M in 2026-Q2, net income similarly declined, and cash from operations fluctuated with a low of -$3.5M in 2025-Q3. The trajectory shows persistent losses and negative cash flow, indicating limited progress on this priority.
“Operating income was -$2.5M and net income was -$2.4M.”
“Operating income was -$2.7M and net income was -$3.0M; cash from operations was -$1.2M.”
“No financials reported.”
“Operating income was -$3.1M and net income was -$3.1M; cash from operations was -$3.5M.”
“Operating income was -$3.2M and net income was -$3.2M; cash from operations was -$0.5M.”
“Operating income was -$2.4M and net income was -$2.4M; cash from operations was -$1.6M.”
“Operating income was -$1.2M and net income was -$1.1M; cash from operations was -$0.8M.”
Progress clinical development of ART27.13 and ART26.12 targeting cancer anorexia-cachexia and neuropathic pain.
Newly stated in 2026-Q1. Management highlighted advancing ART27.13 with encouraging Phase 2 interim data and ART26.12 development. No financial or clinical milestone data provided in the bundle to assess delivery; progress status is mixed based on available information.
“Focused on progressing ART27.13 with Phase 2 CAReS interim data and advancing ART26.12 for neuropathic pain.”
Ensure compliance with Nasdaq listing rules to maintain market listing and investor confidence.
Newly stated in 2026-Q1. Management announced regaining compliance with Nasdaq listing rules 5550(b)(1) and 5620(a). The company is under a mandatory panel monitor for one year. This indicates successful delivery on this regulatory priority as of the latest disclosure.
“Nasdaq confirmed the Company regained compliance with listing rules and will have a panel monitor for one year.”
Implement a 1-for-9 reverse stock split to increase share price and improve marketability and liquidity.
Newly stated in the August 2026 8-K exhibit. Management implemented a 1-for-9 reverse stock split effective August 31, 2026, aiming to improve share price and liquidity. This is a discrete capital allocation action with clear delivery as of the announcement.
Over the trailing year it converted 0.70x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, the US dollar, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
35 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.